Terbinafine-induced subacute cutaneous lupus erythematosus

Dermatology. 2006;212(1):59-65. doi: 10.1159/000089024.

Abstract

Background: Nearly 10% of lupus erythematosus (LE) are drug induced. More than 60 different drugs are involved in iatrogenic LE. We report herein 3 cases of terbinafine-induced LE.

Observations: Three patients receiving terbinafine for a suspected dermatophytic infection developed a subacute cutaneous LE, within 7 weeks following terbinafine introduction. The patients' medical history included sicca syndrome, lung carcinoma and Kikuchi disease, respectively. Clinical remission occurred within 15 weeks following terbinafine withdrawal.

Discussion: Sixteen cases of terbinafine-induced LE have been previously reported, including 13 women. The median age was 54 years. Prior autoimmunity was reported in 10 cases, including 5 pre-existing LE. The median delay between terbinafine introduction and LE onset was 5 weeks. The median time until clinical recovery following terbinafine withdrawal was 8 weeks.

Conclusion: Terbinafine should be prescribed only in patients with proven dermatophytosis. We recommend cautious monitoring in patients with pre-existing autoimmunity. The diagnosis of terbinafine-induced LE should lead to the immediate and definitive withdrawal of the drug.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Antinuclear / blood
  • Antifungal Agents / adverse effects*
  • Antifungal Agents / therapeutic use
  • Female
  • Humans
  • Lupus Erythematosus, Cutaneous / blood
  • Lupus Erythematosus, Cutaneous / chemically induced*
  • Lupus Erythematosus, Cutaneous / pathology
  • Male
  • Middle Aged
  • Naphthalenes / adverse effects*
  • Naphthalenes / therapeutic use
  • Onychomycosis / drug therapy
  • Terbinafine

Substances

  • Antibodies, Antinuclear
  • Antifungal Agents
  • Naphthalenes
  • Terbinafine